| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Transcu Group Ltd (SGX: E15)
E15 Technical Analysis
1
| As on N/A E15 Share Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS. |
E15 Share Price
| Open | N/A | Change | Price | % |
| High | N/A | 1 Day | N/A | N/A |
| Low | N/A | 1 Week | N/A | N/A |
| Close | N/A | 1 Month | N/A | N/A |
| Volume | N/A | 1 Year | N/A | N/A |
| 52 Week High N/A | 52 Week Low N/A | ||||
SGX Singapore Most Active Stocks
| N21 | 131.00 | 0.00% |
| A50 | 0.13 | 0.00% |
| 5DE | 0.02 | 0.00% |
| 576 | 0.15 | 0.00% |
| EG0 | 0.03 | 0.00% |
| C8R | 0.06 | 0.00% |
| B22 | 0.09 | 0.00% |
| 5ME | 0.20 | 0.00% |
| E5H | 0.40 | 0.00% |
| Z74 | 3.75 | 0.00% |
SGX Singapore Top Gainers Stocks
SGX Singapore Top Losers Stocks
| E15 Daily Charts |
E15 Intraday Charts |
Whats New @ Bazaartrend |
E15 Free Analysis |
|
|
E15 Important Levels Intraday
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE |
E15 Target for Month July
| 4th UP TARGET | |
| 3rd UP TARGET | |
| 2nd UP TARGET | |
| 1st UP TARGET | |
| 1st DOWN TARGET | |
| 2nd DOWN TARGET | |
| 3rd DOWN TARGET | |
| 4th DOWN TARGET |
E15 Weekly Target
| 4th UP TARGET | |
| 3rd UP TARGET | |
| 2nd UP TARGET | |
| 1st UP TARGET | |
| 1st DOWN TARGET | |
| 2nd DOWN TARGET | |
| 3rd DOWN TARGET | |
| 4th DOWN TARGET |
E15 Target for Year 2020
| 4th UP TARGET | |
| 3rd UP TARGET | |
| 2nd UP TARGET | |
| 1st UP TARGET | |
| 1st DOWN TARGET | |
| 2nd DOWN TARGET | |
| 3rd DOWN TARGET | |
| 4th DOWN TARGET |
Transcu Group Ltd ( SGX Singapore Symbol : E15 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
E15 Business Profile
Transcu Group Limited engages in the research, development, manufacture, and sale of pharmaceutical and cosmetics products primarily in Singapore, Japan, and the United States. The company operates in three segments: Transdermal Pharmaceutical Devices, Cosmetics, and Green Technology. The Transdermal Pharmaceutical Devices segment develops transdermal drug delivery systems that allow the local and systemic delivery of drugs through the skin into the body. The Cosmetics segment manufactures and sells cosmetic products, including Electore skincare line of products for women, and giulianoFujiwara Electore line of products for men. The Green Technology segment is involved in the development and acquisition of technologies related to the green energy sector, including nano-emulsion fuel system, renewable energy technology, and thermal solutions technology. It also engages in the technological development of gasification of cellulose based biomass from plants; and research and development, manufacture, marketing, and sale of intellectual property management. The company was founded in 1988 and is headquartered in Singapore.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
